As 2026 unfolds, patients managing diabetes and cardiovascular conditions are encountering a patchwork of new coverage rules that could significantly impact their out-of-pocket costs and medication ...

In 2026, the resolution of GLP-1 drug shortages has shifted the focus from supply issues to navigating complex prior authorization requirements. From branded weight-loss and diabetes medications to ...

GLP‑1 and next‑generation obesity drugs are gaining traction across the U.S. and globally, which is good news for investors.